



**FOR IMMEDIATE RELEASE**

**RPS Wins Top Sarasota Innovator Award**

*Recognized by Economic Development Corporation as Healthcare Pioneer*

\* \* \* \* \*

SARASOTA, FL. (September 26, 2011) – Rapid Pathogen Screening, Inc. (RPS®) – a leading developer of rapid, point-of-care diagnostic tests targeting known, new and emerging infections, inflammatory conditions and chemical and bioterrorism threats – has been honored with the 2011 Hall of Fame Innovation Award from Sarasota County’s Economic Development Corporation (EDC). This EDC award recognizes a local business that has instituted an innovative product, service, process, technology or partnership that significantly advances its field of business. RPS was selected over numerous finalists for its groundbreaking point-of-care diagnostic technology that represents a worldwide paradigm shift in how infectious diseases and medical conditions are detected in the physician’s office.

RPS was the brainchild of a family of physicians who identified a vital healthcare deficiency – the need for rapid, affordable and reliable diagnostics to provide more effective patient care at a lower cost.

“What began as an idea to provide better and more effective patient care is now fundamentally changing how clinicians diagnose and treat their patients,” said Dr. Robert Sambursky, president and chief medical officer of RPS. “Our goal is, and always will be, to continue to ensure physicians have the most accurate tools available to provide the best care possible to their patients.”

The company successfully launched the first in a series of diagnostic tests with its FDA-cleared product, the RPS Adeno Detector™. The easy-to-use, in-office test rapidly and accurately detects the viral form of conjunctivitis, or pink eye. The test allows a clinician to make an accurate diagnosis and provide appropriate treatment before the patient leaves the office, thereby reducing the spread of disease.

With its unique, patented technology platform, RPS continues to innovate. The company is developing a wide range of additional rapid diagnostic tests targeting known, new and emerging infections, inflammatory conditions, and chemical and bioterrorism threats. Two of these new tests, AdenoPlus™ and InflammDry™ are currently available internationally.

“RPS is proud to be recognized among the wide range of innovative companies located in Sarasota,” said Thomas Orsini, RPS chief executive officer. “RPS also hopes to work in partnership with the Sarasota County EDC to attract even more innovative companies to the area, particularly in the biotechnology industry.”

**About RPS**

Founded in 2004, Rapid Pathogen Screening, Inc. (RPS) is a leading developer, manufacturer and marketer of rapid, easy-to-use, point-of-care diagnostic tests. The company's revolutionary, patented Direct Sampling Micro-Filtration (DSMF) technology and patent-pending Direct Multi-Planar Chromafiltography (DMC) technology allow for the current and future development of tests to confirm patients with infectious diseases and agents, inflammatory conditions, and asymptomatic exposure to chemical warfare and bio-terrorism agents. RPS tests have superior sensitivity and specificity and can be easily performed by a clinician's staff without extensive training or additional equipment.

# # #

**For additional information, contact:**

Laura Lovejoy, Manager of Business Development, RPS, 941.556.1864